Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

19
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
19
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

22
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
22
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.7K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

31
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
31
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

24
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
24
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

130
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
130

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

DIGIT-HF: Results From the Win Ratio Analyses.

Circulation. Heart failure·2026
Same author

Ventricular conduction is a marker for arrhythmic risk in SCN5A-E1784K overlap sodium channel disease.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same author

Predictors of Favorable Neurological Outcomes Following Atrioesophageal Fistula After Radiofrequency Catheter Ablation for Atrial Fibrillation: A Subanalysis of the POTTER-AF Study.

Circulation. Arrhythmia and electrophysiology·2026
Same author

Influence of proton pump inhibitors on the incidence and clinical course of oesophageal fistula following catheter ablation for atrial fibrillation: a subanalysis of the POTTER-AF study.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2025
Same author

Seascape connectivity: evidence, knowledge gaps and implications for temperate coastal ecosystem restoration practice and policy.

npj ocean sustainability·2025
Same author

Management of de novo heart failure with reduced ejection fraction: guideline-recommended medical therapy comes first.

European heart journal·2025
Same journal

[Extrasystoles in endurance athletes].

Herzschrittmachertherapie & Elektrophysiologie·2026
Same journal

[AI-Assisted ECG diagnostics : Classical test statistics still apply].

Herzschrittmachertherapie & Elektrophysiologie·2026
Same journal

[Perioperative complications during transvenous pacemaker and defibrillator implantation].

Herzschrittmachertherapie & Elektrophysiologie·2026
Same journal

Herzschrittmachertherapie & Elektrophysiologie·2026
Same journal

[Late complications after atrial fibrillation ablation : Diagnosis and management].

Herzschrittmachertherapie & Elektrophysiologie·2026
Same journal

[Position paper of the German Society of Cardiology-quality criteria for performing catheter ablation of atrial fibrillation: executive summary].

Herzschrittmachertherapie & Elektrophysiologie·2026
See all related articles

Related Experiment Video

Updated: Aug 12, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.6K

The Heart Failure Optimization Study (HF-OPT): rationale and design.

R Sanchez1, D Duncker2, B Colley3

  • 1HCA Florida Heart Institute, St. Petersburg, FL, USA.

Herzschrittmachertherapie & Elektrophysiologie
|January 25, 2023
PubMed
Summary
This summary is machine-generated.

This study evaluates left ventricular function recovery in heart failure patients after 3 months of optimal medical therapy. Results may influence decisions on implantable cardioverter-defibrillator implantation for primary prevention.

Keywords:
Guideline-directed medical therapyImplantable cardioverter-defibrillatorLeft ventricular ejection fractionWearable cardioverter-defibrillator

More Related Videos

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure
07:13

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure

Published on: April 30, 2020

6.5K
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.5K

Related Experiment Videos

Last Updated: Aug 12, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.6K
A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure
07:13

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure

Published on: April 30, 2020

6.5K
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.5K

Area of Science:

  • Cardiology
  • Heart Failure Research
  • Medical Device Technology

Background:

  • Current guidelines recommend delaying implantable cardioverter-defibrillator (ICD) implantation for primary prevention in heart failure with reduced ejection fraction (HFrEF) until optimal guideline-directed medical therapy (GDMT) is achieved for at least 3 months.
  • Optimizing GDMT can extend beyond the initial 3-month period, necessitating further evaluation of cardiac function recovery.
  • The Heart Failure Optimization Study (HF-OPT) addresses the need to understand left ventricular function recovery beyond this initial 3-month timeframe in newly diagnosed HFrEF patients.

Purpose of the Study:

  • To assess the recovery of left ventricular ejection fraction (LVEF) in patients with newly diagnosed HFrEF.
  • To evaluate the rate of LVEF improvement beyond 3 months of optimized GDMT.
  • To determine if LVEF can recover to >35% between 90 and 180 days post-diagnosis.

Main Methods:

  • The HF-OPT is a multicenter study with two non-randomized phases: a registry and a study phase.
  • Patients receive a wearable cardioverter-defibrillator (WCD) for the first 90 days and are enrolled in a pre-study registry.
  • Eligible patients undergo LVEF reassessment at 90, 180, and 360 days post-discharge. Approximately 600 subjects are planned for the study portion.

Main Results:

  • The primary objective is to measure the rate of LVEF recovery to >35% between 90 and 180 days.
  • Secondary endpoints include monitoring all-cause mortality and analyzing data from the WCD regarding arrhythmias and shocks.
  • Approximately one-third of the ~600 enrolled subjects are expected to have reduced LVEF at the start of the study phase (day 90).

Conclusions:

  • The HF-OPT study will provide crucial data on LVEF recovery rates between 90 and 180 days in HFrEF patients undergoing GDMT titration.
  • Findings may inform clinical decisions regarding the timing and necessity of primary prophylactic ICD implantation.
  • Understanding functional recovery is key to refining treatment strategies for HFrEF.